Effect of an intravenous gammaglobulin preparation on the opsonophagocytic activity of preterm serum against coagulase-negative staphylococci

Acta paediatrica Scandinavica
A EtzioniD Merzbach

Abstract

Recent reports have described cases of septicaemia caused by coagulase-negative staphylococci in preterm neonates, mainly due to the use of artificial intravenous devices. It was of interest to examine if intravenous immunoglobulin therapy, known to be effective in group B streptococcal infections of neonates, had a similar beneficial effect in coagulase-negative staphylococcal infections. Opsonophagocytosis of coagulase-negative staphylococci by normal polymorphonuclear leukocytes in the presence of cord blood serum supplemented with the commercial IgG preparation 'Sandoglobulin' was investigated, using luminol-dependent chemiluminescence. It was found that with two different coagulase-negative staphylococcal strains, Sandoglobulin had a concentration-dependent enhancing effect on the chemiluminescent response. This effect was demonstrated in the presence of native as well as inactivated cord blood serum and in the presence of sera from preterm infants (28-33 weeks). It is concluded that intravenous Sandoglobulin therapy may be effective in the treatment of preterm infants with severe coagulase-negative staphylococcal infections.

References

Jan 1, 1975·Journal of Clinical Microbiology·W E Kloos, K H Schleifer
Mar 1, 1987·The Journal of Pediatrics·G ChiricoA G Ugazio
Jun 1, 1986·Journal of Bioluminescence and Chemiluminescence·M J Harber, N Topley
Jul 1, 1986·The Journal of Infectious Diseases·C J BakerM S Edwards
Apr 1, 1987·Journal of Clinical Microbiology·W M DunneT R Franson
Aug 1, 1986·Journal of Medical Microbiology·L A Clark, C S Easmon
Sep 1, 1986·The Journal of Pediatrics·D SidiropoulosS Barandun
Jan 1, 1987·Journal of Pediatric Gastroenterology and Nutrition·A EtzioniP Sujov
Sep 1, 1971·American Journal of Clinical Pathology·H E EvansL Glass
Feb 1, 1982·Clinical Immunology and Immunopathology·T D HoranT A McPherson
Jul 1, 1981·The Journal of Pediatrics·R ShapiroA F Malan
Oct 1, 1981·Archives of Disease in Childhood·O BattistiP A Davies
Dec 11, 1985·The Journal of Applied Behavioral Science·J P Howell, P W Dorfman

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.